Karyopharm EVP Chief Development Officer Ran Frenkel to depart Aug 15; Stuart Poulton promoted to succeed

Karyopharm Therapeutics Inc.

Ran Frenkel to cease as EVP, Chief Development Officer effective August 15, 2022.
Stuart Poulton promoted to EVP, Chief Development Officer effective July 27, 2022.
Poulton previously SVP, Strategy and Portfolio Management since Feb 2022; 25+ years at AbbVie, Amgen, Eli Lilly.
Data sciences, clinical pharmacology, data management, medical writing, quality consolidated under Poulton or CMO Reshma Rangwala.
Company plans separation and consulting agreements with Frenkel.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Stuart Poulton

Executive Vice President, Chief Development Officer

KPTI · Karyopharm Therapeutics Inc.

Effective: 2022-07-27
Filed: July 28, 2022, 7:59 PM ET

Stuart Poulton, who has served as the Company’s Senior Vice President, Strategy and Portfolio Management since February 2022, has been promoted to Executive Vice President, Chief Development Officer, effective July 27, 2022.

Departed

Ran Frenkel

Executive Vice President, Chief Development Officer

KPTI · Karyopharm Therapeutics Inc.

Effective: 2022-08-15
Successor: Stuart Poulton
Filed: July 28, 2022, 7:59 PM ET

On July 26, 2022, Karyopharm Therapeutics Inc. (the “Company”) and Ran Frenkel agreed that Mr. Frenkel will cease to serve as the Company’s Executive Vice President, Chief Development Officer effective August 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stuart Poulton changed role as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics Inc..

Action: promoted
Role: Executive Vice President, Chief Development Officer

Exact text from the filing

Stuart Poulton, who has served as the Company’s Senior Vice President, Strategy and Portfolio Management since February 2022, has been promoted to Executive Vice President, Chief Development Officer, effective July 27, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ran Frenkel departed as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics Inc..

Action: cease to serve
Role: Executive Vice President, Chief Development Officer

Exact text from the filing

On July 26, 2022, Karyopharm Therapeutics Inc. (the “Company”) and Ran Frenkel agreed that Mr. Frenkel will cease to serve as the Company’s Executive Vice President, Chief Development Officer effective August 15, 2022.

View on SEC.gov

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-204195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.